Krsnaa Diagnostics Ltd. is one of India's largest diagnostic service providers, operating diagnostic centers across public-private partnerships (PPPs) and private hospital networks. The company offers radiology, pathology, and teleradiology solutions. With an expanding national footprint and tie-ups with state governments, the stock is currently trading at ₹785.50, showing technical signs of accumulation after a prolonged corrective phase.
Krsnaa Diagnostics Ltd. – FY22–FY25
Snapshot Sales – ₹415 Cr → ₹489 Cr → ₹574 Cr → ₹642 Cr – Consistent top-line growth driven by PPPs
Net Profit – ₹43.6 Cr → ₹54.2 Cr → ₹64.9 Cr → ₹82.7 Cr – Strong margin profile with cost control and volume
Company Order Book – Moderate → Strong → Strong → Strong – Robust pipeline from state diagnostic projects Dividend Yield (%) – 0.00% → 0.00% → 0.00% → 0.00% – No payouts; reinvestment-led growth strategy
Operating Performance – Moderate → Moderate → Strong → Strong – Operating leverage kicking in
Equity Capital – ₹31.78 Cr (constant) – Stable equity base, no dilution
Total Debt – ₹123 Cr → ₹112 Cr → ₹102 Cr → ₹93 Cr – Deleveraging consistently
Total Liabilities – ₹435 Cr → ₹456 Cr → ₹478 Cr → ₹505 Cr – Aligned with expansion and capacity build-up
Fixed Assets – ₹155 Cr → ₹170 Cr → ₹186 Cr → ₹205 Cr – Gradual asset base expansion to support lab network
Latest Highlights
FY25 net profit rose 27.4% YoY to ₹82.7 Cr; revenue increased 11.8% to ₹642 Cr
EPS: ₹26.02 | EBITDA Margin: 24.7% | Net Margin: 12.9%
Return on Equity: 13.91% | Return on Assets: 7.49%
Promoter holding: 27.34% | Dividend Yield: 0.00%
New PPP contracts in Maharashtra and West Bengal began contributing to volumes
Focus on expanding radiology-led diagnostics and digital teleradiology infrastructure
Technical Snapshot Krsnaa Diagnostics is trading at ₹785.50 with an RSI of 50.33, indicating neutral momentum with signs of base formation. Price is consolidating just above a key support zone around ₹728.45. Volume is gradually increasing. If buying interest continues, potential medium-term targets emerge near ₹944.60, ₹1,031.30, and ₹1,141.70, based on Fibonacci retracement projections.
Business Growth Verdict Yes, Krsnaa Diagnostics is expanding steadily with a scalable and asset-light model
Margins and profits are improving on the back of volume growth
Balance sheet is strengthening with steady debt reduction
Strategic growth focused on underserved geographies via PPPs and digital health infrastructure
Final Investment Verdict Krsnaa Diagnostics presents an attractive scalable opportunity in India’s expanding diagnostics ecosystem. With sustained earnings momentum, rising efficiency, and a robust public-private client base, the company is building a dependable long-term platform. Although the promoter stake is modest and dividends are absent, the earnings quality, healthcare tailwinds, and improving operating leverage position the stock as a strong compounder candidate in the diagnostics segment.
Krsnaa Diagnostics Ltd. – FY22–FY25
Snapshot Sales – ₹415 Cr → ₹489 Cr → ₹574 Cr → ₹642 Cr – Consistent top-line growth driven by PPPs
Net Profit – ₹43.6 Cr → ₹54.2 Cr → ₹64.9 Cr → ₹82.7 Cr – Strong margin profile with cost control and volume
Company Order Book – Moderate → Strong → Strong → Strong – Robust pipeline from state diagnostic projects Dividend Yield (%) – 0.00% → 0.00% → 0.00% → 0.00% – No payouts; reinvestment-led growth strategy
Operating Performance – Moderate → Moderate → Strong → Strong – Operating leverage kicking in
Equity Capital – ₹31.78 Cr (constant) – Stable equity base, no dilution
Total Debt – ₹123 Cr → ₹112 Cr → ₹102 Cr → ₹93 Cr – Deleveraging consistently
Total Liabilities – ₹435 Cr → ₹456 Cr → ₹478 Cr → ₹505 Cr – Aligned with expansion and capacity build-up
Fixed Assets – ₹155 Cr → ₹170 Cr → ₹186 Cr → ₹205 Cr – Gradual asset base expansion to support lab network
Latest Highlights
FY25 net profit rose 27.4% YoY to ₹82.7 Cr; revenue increased 11.8% to ₹642 Cr
EPS: ₹26.02 | EBITDA Margin: 24.7% | Net Margin: 12.9%
Return on Equity: 13.91% | Return on Assets: 7.49%
Promoter holding: 27.34% | Dividend Yield: 0.00%
New PPP contracts in Maharashtra and West Bengal began contributing to volumes
Focus on expanding radiology-led diagnostics and digital teleradiology infrastructure
Technical Snapshot Krsnaa Diagnostics is trading at ₹785.50 with an RSI of 50.33, indicating neutral momentum with signs of base formation. Price is consolidating just above a key support zone around ₹728.45. Volume is gradually increasing. If buying interest continues, potential medium-term targets emerge near ₹944.60, ₹1,031.30, and ₹1,141.70, based on Fibonacci retracement projections.
Business Growth Verdict Yes, Krsnaa Diagnostics is expanding steadily with a scalable and asset-light model
Margins and profits are improving on the back of volume growth
Balance sheet is strengthening with steady debt reduction
Strategic growth focused on underserved geographies via PPPs and digital health infrastructure
Final Investment Verdict Krsnaa Diagnostics presents an attractive scalable opportunity in India’s expanding diagnostics ecosystem. With sustained earnings momentum, rising efficiency, and a robust public-private client base, the company is building a dependable long-term platform. Although the promoter stake is modest and dividends are absent, the earnings quality, healthcare tailwinds, and improving operating leverage position the stock as a strong compounder candidate in the diagnostics segment.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。